Table 3.
Relapse and NRM
| n | Relapse | NRM | |||||
|---|---|---|---|---|---|---|---|
| 3-y (95% CI) | HR (95% CI)* | P * | 3-y (95% CI) | HR (95% CI)* | P * | ||
| Donor type | |||||||
| MUD | 974 | 0.34 (0.31, 0.37) | Reference | .68 | 0.24 (0.21, 0.27) | Reference | .19 |
| Haplo | 487 | 0.37 (0.32, 0.41) | 0.95 (0.75, 1.21) | 0.24 (0.20, 0.29) | 1.19 (0.92, 1.55) | ||
| Recipient age, y | |||||||
| <30 | 579 | 0.31 (0.27, 0.36) | Reference | .038 | 0.21 (0.18, 0.25) | Reference | .006 |
| 30-39 | 281 | 0.40 (0.34, 0.46) | 1.34 (1.05, 1.72) | 0.20 (0.16, 0.25) | 1.10 (0.80, 1.49) | ||
| 40-54 | 350 | 0.33 (0.27, 0.38) | 1.15 (0.90, 1.46) | 0.26 (0.21, 0.31) | 1.33 (1.01, 1.76) | ||
| ≥55 | 251 | 0.40 (0.34, 0.47) | 1.39 (1.07, 1.82) | 0.33 (0.27, 0.39) | 1.73 (1.26, 2.36) | ||
| KPS † | |||||||
| 90-100 | 978 | 0.35 (0.32, 0.38) | Reference | .76 | 0.21 (0.18, 0.24) | Reference | <.001 |
| ≤80 | 388 | 0.36 (0.31, 0.41) | 0.97 (0.79, 1.19) | 0.31 (0.26, 0.36) | 1.50 (1.18, 1.89) | ||
| ALL subtype | |||||||
| B-ALL | 1044 | 0.33 (0.30, 0.36) | Reference | .56 | 0.25 (0.22, 0.27) | Reference | .70 |
| T-ALL | 322 | 0.39 (0.33, 0.44) | 1.10 (0.89, 1.37) | 0.23 (0.18, 0.28) | 1.00 (0.75, 1.33) | ||
| Other | 95 | 0.40 (0.28, 0.51) | 1.15 (0.79, 1.65) | 0.22 (0.14, 0.32) | 0.83 (0.53, 1.30) | ||
| Months from diagnosis to HCT | |||||||
| ≤6 | 398 | 0.32 (0.27, 0.37) | Reference | .25 | 0.21 (0.17, 0.26) | Reference | .11 |
| >6-12 | 510 | 0.28 (0.24, 0.32) | 0.80 (0.62, 1.04) | 0.24 (0.21, 0.28) | 1.31 (0.99, 1.73) | ||
| >12 | 553 | 0.43 (0.39, 0.48) | 0.86 (0.65, 1.14) | 0.26 (0.22, 0.29) | 1.41 (0.98, 2.03) | ||
| HCT Comorbidity Index † | |||||||
| 0 | 147 | 0.34 (0.24, 0.44) | Reference | .89 | 0.23 (0.14, 0.32) | Reference | .39 |
| 1-2 | 92 | 0.43 (0.30, 0.55) | 1.09 (0.66, 1.78) | 0.28 (0.18, 0.38) | 1.36 (0.79, 2.34) | ||
| >2 | 94 | 0.36 (0.26, 0.47) | 0.96 (0.57, 1.61) | 0.24 (0.12, 0.39) | 0.95 (0.52, 1.74) | ||
| Donor age, y † | |||||||
| <30 | 342 | 0.37 (0.31, 0.43) | Reference | .99 | 0.24 (0.19, 0.29) | Reference | .50 |
| 30-49 | 443 | 0.37 (0.32, 0.42) | 0.99 (0.77, 1.27) | 0.21 (0.18, 0.26) | 0.94 (0.69, 1.27) | ||
| ≥50 | 127 | 0.33 (0.25, 0.42) | 0.99 (0.69, 1.41) | 0.26 (0.18, 0.34) | 1.19 (0.78, 1.81) | ||
| Female-to-male HCT † | |||||||
| No | 1172 | 0.34 (0.31, 0.37) | Reference | .087 | 0.24 (0.22, 0.27) | Reference | .70 |
| Yes | 262 | 0.39 (0.33, 0.46) | 1.22 (0.97, 1.53) | 0.22 (0.17, 0.27) | 0.94 (0.70, 1.27) | ||
| CMV serostatus † | |||||||
| D+/R+ | 581 | 0.37 (0.33, 0.41) | Reference | .062 | 0.24 (0.20, 0.28) | Reference | .14 |
| D+/R− | 130 | 0.30 (0.22, 0.38) | 0.89 (0.62, 1.28) | 0.24 (0.17, 0.32) | 1.11 (0.78, 1.58) | ||
| D−/R+ | 366 | 0.32 (0.27, 0.37) | 0.85 (0.67, 1.07) | 0.25 (0.20, 0.30) | 1.04 (0.79, 1.36) | ||
| D−/R− | 318 | 0.40 (0.34, 0.45) | 1.22 (0.96, 1.56) | 0.19 (0.15, 0.24) | 0.74 (0.54, 1.02) | ||
| Stem cell source | |||||||
| PB | 1056 | 0.35 (0.32, 0.38) | Reference | .41 | 0.24 (0.21, 0.26) | Reference | .40 |
| BM | 405 | 0.36 (0.31, 0.41) | 1.09 (0.88, 1.35) | 0.25 (0.21, 0.29) | 1.12 (0.87, 1.44) | ||
| Transplant period | |||||||
| 2005-2012 | 695 | 0.32 (0.28, 0.35) | Reference | .099 | 0.26 (0.23, 0.29) | Reference | .027 |
| 2013-2018 | 766 | 0.38 (0.34, 0.42) | 1.17 (0.97, 1.41) | 0.23 (0.19, 0.26) | 0.78 (0.63, 0.97) | ||
*
Based on the multivariable proportional subdistribution hazards model for competing risks adjusted for age, female donor to male recipient, CMV serostatus, and transplant period for relapse, adjusted for age, KPS, and transplant period for NRM, and stratified by matching variables: sex, cytogenetic risk, Ph status, disease stage, and conditioning intensity. The robust sandwich covariance matrix estimate was used to adjust for within-center correlation.
†
Patients who had missing values were included in the model when the variable was covariates, but were excluded when the variable was predictor of interest.